Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more cancer cells. Monoclonal antibodies, such as
rituximab, can block cancer growth in different ways. Some block the ability of cancer cells
to grow and spread. Others find cancer cells and help kill them or carry cancer-killing
substances to them. Giving combination chemotherapy together with rituximab may kill more
cancer cells.
PURPOSE: This phase II trial is studying how well giving combination chemotherapy together
with rituximab works in treating patients with newly diagnosed Burkitt's lymphoma or
leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins